CBS 2019
CBSMD教育中心
English

充血性心力衰竭

科研文章

荐读文献

Angiotensin–neprilysin inhibition versus enalapril in heart failure A randomized controlled trial to evaluate the safety and efficacy of cardiac contractility modulation in patients with systolic heart failure: rationale, design, and baseline patient characteristics. In acute HF and iron deficiency, IV ferric carboxymaltose reduced HF hospitalizations, but not CV death, at 1 y Rationale and design of the comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial Vaccination Trends in Patients With Heart Failure - Insights From Get With The Guidelines–Heart Failure Clinical epidemiology of heart failure with preserved ejection fraction (HFpEF) in comparatively young hospitalized patients 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society SGLT-2 Inhibitors and Cardiovascular Risk: An Analysis of CVD-REAL Heart Failure With Preserved Ejection Fraction in the Young A pragmatic approach to the use of inotropes for the management of acute and advanced heart failure: An expert panel consensus

Clinical Trial2014 Sep 11;371(11):993-1004.

JOURNAL:N Engl J Med. Article Link

Angiotensin–neprilysin inhibition versus enalapril in heart failure

McMurray JJ, Packer M, PARADIGM-HF Investigators and Committees. Keywords: angiotensin receptor-neprilysin inhibitor LCZ696; enalapril; HFrEF; mortality; survival; hospitalization for heart failure

FULL TEXT PDF